Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma

Expert Opinion on Biological Therapy

Volumn 16, Issue 3, 2016, Pages 389-396

  Spain, Lavinia ^a   Larkin, James ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Advanced melanoma; Anti CTLA 4; Anti PD 1; Ipilimumab; Nivolumab; Safety

Indexed keywords

IPILIMUMAB; NIVOLUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADAPTIVE IMMUNITY; ADVANCED CANCER; ARTICLE; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; HYPOPHYSITIS; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SIDE EFFECT; DISEASE FREE SURVIVAL; DISEASE MANAGEMENT; IMMUNOLOGY; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE MANAGEMENT; DISEASE-FREE SURVIVAL; HUMANS; MELANOMA;

EID: 84957941892     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2016.1141195     Document Type: Article

References (38)

1. Erdmann F, Lortet-Tieulent J, Schüz J, et al. International trends in the incidence of malignant melanoma 1953-2008-are recent generations at higher or lower risk? Int J Cancer J Int Du Cancer. 2013;132(2):385-400. doi:10.1002/ijc.27616.
2. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clinic Oncol: official J Am Soc Clin Oncol. 2009;27 (36):6199-6206. doi:10.1200/JCO.2009.23.4799.
3. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723. doi:10.1056/NEJMoa1003466.
4. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-330. doi:10.1056/NEJMoa1412082.
5. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015 May 31 doi:10.1056/NEJMoa1504030.
6. Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010;107 (9):4275-4280. doi:10.1073/pnas.0915174107.
7. Selby MJ, Engelhardt JJ, Lu L, et al. Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models. American Society of Clinical Oncology (ASCO). J Clin Oncol. 2013;31(suppl; abstr 3061). Chicago; 2013. doi:10.1200/JCO.2013.49.0219.
8. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. New Eng J Med. 2015 Apr 20 doi:10.1056/NEJMoa1414428.
9. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. New Eng J Med. 2015 Apr 19 doi:10.1056/NEJMoa1503093.
10. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015 May 29 doi:10.1016/S0140-6736(15)60898-4.
11. Robert C, Karaszewska B, Schachter J, et al. Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. European Cancer Congress (ECC). Vienna: EurJ Cancer 2015;2015(Supp 3).
12. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516. doi:10.1056/NEJMoa1103782.
13. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial. Lancet. 2012;380 (9839):358-365. doi:10.1016/S0140-6736(12)60868-X.
14. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087-1095. doi:10.1016/S1470-2045(12) 70431-X.
15. BMS. Yervoy (Ipilimumab)-Highlights of Prescribing Information; 2011 [cited 2015 Nov 17]; Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/125377s0000lbl.pdf.
16. BMS. Opdivo (Nivolumab)-Highlights of Prescribing Information; 2014 [cited 2015 Nov 17]; Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/125554lbl.pdf.
17. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009;229(1):12-26. doi:10.1111/j.1600-065X.2009.00770.x.
18. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182(2):459-465.
19. Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206(8):1717-1725. doi:10.1084/jem.20082492.
20. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322 (5899):271-275. doi:10.1126/science.1160062.
21. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271 (5256):1734-1736.
22. Selby MJ, Engelhardt JJ, Quigley M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2013;1(1):32-42. doi:10.1158/2326-6066.CIR-13-0013.
23. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. The. J Exp Med. 2000;192(7):1027-1034.
24. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261-268. doi:10.1038/85330.
25. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793-800. doi:10.1038/nm730.
26. Rozali EN, Hato SV, Robinson BW, et al. Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol. 2012;2012:656340. doi:10.1155/2012/656340.
27. Fife BT, Pauken KE, Eagar TN, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCRinduced stop signal. Nat Immunol. 2009;10(11):1185-1192. doi:10.1038/ni.1790.
28. Blank C, Brown I, Peterson AC, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004;64 (3):1140-1145.
29. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548-558. doi:10.1038/clpt.2008.170.
30. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-133. doi:10.1056/NEJMoa1302369.
31. Sznol M, Kluger H, Callahan M, et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). ASCO; J Clin Oncol. 2014;32:5s. (suppl; abstr LBA9003); 2014; Chicago; 2014.
32. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067). European Cancer Congress; 2015. Vienna: Eur J Cancer. 2015;51(Supp S3).
33. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clinic Oncol: official J Am Soc Clin Oncol. 2014;32 (10):1020-1030. doi:10.1200/JCO.2013.53.0105.
34. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375-384. doi:10.1016/S1470-2045(15)70076-8.
35. Kelderman S, Heemskerk B, Van Tinteren H, et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol, Immunotherapy: CII. 2014;63(5):449-458. doi:10.1007/s00262-014-1528-9.
36. Hugo W, Shi H, Sun L, et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell. 2015;162(6):1271-1285. doi:10.1016/j. cell.2015.07.061.
37. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30 (21):2691-2697.
38. Weber J, Antonia S, Topalian SL, et al. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): a pooled analysis. J Clin Oncol. 2015;33 (suppl; abstr 9018)